Expert review on poliovirus immunity and transmission

Risk Analysis

Volumn 33, Issue 4, 2013, Pages 544-605

  Duintjer Tebbens, Radboud J ^a   Pallansch, Mark A ^b   Chumakov, Konstantin M ^c   Halsey, Neal A ^d   Hovi, Tapani ^e   Minor, Philip D ^f   Modlin, John F ^g   Patriarca, Peter A ^h   Sutter, Roland W ⁱ   Wright, Peter F ^g   Wassilak, Steven G F ^j   Cochi, Stephen L ^j   Kim, Jong Hoon ^a   Thompson, Kimberly M ^a  

^a Kid Risk Inc   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^f NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^g DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^h BIOLOGICS CONSULTING GROUP INC   (United States)

ⁱ WORLD HEALTH ORGANIZATION   (Switzerland)

^j CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

more..

Author keywords

Dynamic modeling; Polio eradication; Risk management

Indexed keywords

CENTERS FOR DISEASE CONTROL AND PREVENTIONS; EXPOSURE HISTORY; INTERNATIONAL EXPERTS; LIMITED DATA; MODEL INPUTS; POLIO ERADICATION; QUANTITATIVE MODELS; TRANSMISSION ROUTE;

DYNAMIC MODELS; PHYSIOLOGY; RISK ASSESSMENT; VACCINES; VIRUSES;

RISK MANAGEMENT;

ORAL POLIOMYELITIS VACCINE;

DISEASE SPREAD; DISEASE TRANSMISSION; HEALTH RISK; IMMUNITY; LITERATURE REVIEW; PUBLIC HEALTH; RISK ASSESSMENT; VACCINE; VIRUS;

ARTICLE; DISEASE TRANSMISSION; HUMAN; IMMUNOLOGY; POLIOMYELITIS; PUBLIC HEALTH SERVICE; UNITED STATES;

CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); HUMANS; POLIOMYELITIS; POLIOVIRUS VACCINE, ORAL; UNITED STATES;

POLIOVIRUS;

EID: 84875950812     PISSN: 02724332     EISSN: 15396924     Source Type: Journal    
DOI: 10.1111/j.1539-6924.2012.01864.x     Document Type: Article

References (147)

1. World Health Assembly. Global Eradication of Poliomyelitis by the Year 2000 (Resolution 41.28). Geneva: World Health Organization, 1988. Available at: http://www.who.int/csr/ihr/polioresolution4128en.pdf Accessed June 21, 2012.
2. World Health Organization. Global Polio Eradication Initiative - Strategic Plan 2010-2012. Geneva; 2010. Report No.: WHO/Polio/10.01.
3. World Health Assembly. Poliomyelitis: Mechanism for Management of Potential Risks to Eradication (Resolution 61.1). Geneva: World Health Organization, 2008. Available at: http://www.polioeradication.org/content/general/WHA61_Resolution_English.pdf, Accessed June 21, 2012.
4. Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SG, Kim J-H, Cochi SL. Pre-eradication vaccine policy options for poliovirus infection and disease control. Risk Analysis, 2013; 33(4):516-543.
5. Sangrujee N, Duintjer Tebbens RJ, Cáceres VM, Thompson KM. Policy decision options during the first 5 years following certification of polio eradication. Medscape General Medicine, 2003; 5(4):35.
6. Thompson KM, Duintjer Tebbens RJ. Current polio global eradication and control policy options: Perspectives from modeling and prerequisites for OPV cessation. Expert Reviews of Vaccines, 2012; 11(4):449-459.
7. Anderson RM, May RM. Infectious Diseases of Humans: Dynamics and Control. New York: Oxford University Press, 1991.
8. Duintjer Tebbens RJ, Pallansch MA, Kew OM, Cáceres VM, Sutter RW, Thompson KM. A dynamic model of poliomyelitis outbreaks: Learning from the past to help inform the future. American Journal of Epidemiology, 2005; 162(4):358-372.
9. Duintjer Tebbens RJ, Pallansch MA, Kew OM, Cáceres VM, Jafari H, Cochi SL, Aylward RB, Thompson KM. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Analysis, 2006; 26(6):1471-1505.
10. Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary HE, Jr., Alexander JP, Jr., Jafari H, Cochi SL, Thompson KM. Uncertainty and sensitivity analyses of a decision analytic model for post-eradication polio risk management. Risk Analysis, 2008; 28(4):855-876.
11. Edmunds WJ, Medley GF, Nokes DJ. Evaluating the cost-effectiveness of vaccination programmes: A dynamic perspective. Statistics in Medicine, 1999; 18(23):3263-3282.
12. Thompson KM, Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary HE, Jr., Alexander JP, Jr., Jafari H, Cochi SL. The risks, costs, and benefits of possible future global policies for managing polioviruses. American Journal of Public Health, 2008; 98(7):1322-1330.
13. Duintjer Tebbens RJ, Thompson KM, Hunink M, Mazzuchi TM, Lewandowski D, Kurowicka D, Cooke RM. Uncertainty and sensitivity analyses of a dynamic economic evaluation model for vaccination programs. Medical Decision Making, 2008; 28(2):182-200.
14. Sutter RW, Kew OM, Cochi SL. Poliovirus vaccine-live. Pp. 631-686 in Plotkin SA, Orenstein WA, Offit PA (eds). Vaccines. 5th ed. Philadelphia, PA: Saunders Elsevier, 2008.
15. Plotkin SA, Vidor E. Poliovirus vaccine-Inactivated. Pp. 605-630 in Plotkin SA, Orenstein WA, Offit PA (eds). Vaccines. 5th ed. Philadelphia, PA: Saunders Elsevier, 2008.
16. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SGF, Cochi SL, Kim J-H, Thompson KM. Review and assessment of poliovirus immunity and transmission: Synthesis of knowledge gaps and identification of research needs. Risk Analysis, 2013; 33(4):606-646.
17. Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SGF, Cochi SL. Modeling population immunity to support efforts to end the transmission of live polioviruses. Risk Analysis, 2013; 33(4):647-663.
18. Chen RT, Hausinger S, Dajani AS, Hanfling M, Baughman AL, Pallansch MA, Patriarca PA. Seroprevalence of antibody against poliovirus in inner-city preschool children. Journal of the American Medical Association, 1996; 275(21):1639-1645.
19. Benyesh-Melnick M, Melnick JL, Rawls WE, Wimberly I, Barrera Ora J, Ben-Porath E, Rennick V. Studies of the immunogenicity, communicability and genetic stability of oral poliovaccine administered during the winter. American Journal of Epidemiology, 1967; 86(1):112-136.
20. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. Combined immunization of infants with oral and inactivated poliovirus vaccines: Results of a randomized trial in the Gambia, Oman, and Thailand. WHO collaborative study group on oral and inactivated poliovirus vaccines. Bulletin of the World Health Organization, 1996; 74(3):253-268.
21. Más Lago P, Bravo JR, Andrus JK, Comellas MM, Galindo MA, de Quadros CA, Bell E. Lesson from Cuba: Mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies. Bulletin of the World Health Organization, 1994; 72(2):221-225.
22. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. Combined immunization of infants with oral and inactivated poliovirus vaccines: Results of a randomized trial in the Gambia, Oman, and Thailand. WHO collaborative study group on oral and inactivated poliovirus vaccines. Journal of Infectious Diseases, 1997; 175(Suppl 1):S215-S227.
23. Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: Review. Reviews of Infectious Diseases, 1991; 13:926-939.
24. Ghendon YZ, Sanakoyeva II. Comparison of the resistance of the intestinal tract to poliomyelitis virus (Sabin's strains) in persons after naturally and experimentally acquired immunity. Acta Virologica, 1961; 5:265-273.
25. Henry JL, Jaikaran ES, Mason PJ, Barnes JM, Beale AJ. A study of polio vaccination in infancy: Excretion following challenge with live virus by children given killed or living poliovaccine. Journal of Hygiene Cambridge, 1966; 64:105-120.
26. Onorato IM, Modlin JF, McBean MA, Thoms ML, Losonsky GA, Bernier RH. Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. Journal of Infectious Diseases, 1991; 163:1-6.
27. Melnick JL. Poliovirus and other enteroviruses. Pp. 583-663 in Evans AS, Kaslow RA (eds). Viral Infections of Humans: Epidemiology and Control. 4th ed. New York: Plenum Medical, 1997.
28. Fine PEM, Carneiro IAM. Transmissibility and persistence of oral poliovirus vaccine viruses: Implications for the global poliomyelitis eradication initiative. London: Infectious Disease Epidemiology Unit, Department of Infectious and Tropical Diseases, London School of Hygiene, 1998 May.
29. Rahmandad H, Hu K, Duintjer Tebbens RJ, Thompson KM. Development of an individual-based model for polioviruses: Implications of the selection of network type and outcome metrics. Epidemiology and Infection, 2010; 139(6):836-848.
30. Thompson KM, Duintjer Tebbens RJ. Retrospective cost-effectiveness analyses for polio vaccination in the United States. Risk Analysis, 2006; 26(6):1423-1440.
31. Thompson KM, Duintjer Tebbens RJ. Eradication versus control for poliomyelitis: An economic analysis. Lancet, 2007; 369(9570):1363-1371.
32. Halsey N, Galazka A. The efficacy of DPT and oral poliomyelitis immunization schedules initiated from birth to 12 weeks of age. Bulletin of the World Health Organization, 1985; 63(6):1151-69.
33. Murdin AD, Barreto L, Plotkin SA. Inactivated poliovirus vaccine: Past and present experience. Vaccine, 1996; 14(8):735-746.
34. Alexander JP, Jr., Gary HE, Jr., Pallansch MA. Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: A review of the literature. Journal of Infectious Diseases, 1997; 175(Suppl. 1):S176-S182.
35. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. British Medical Journal, 2008; 336:924-926.
36. Más Lago P. Eradication of poliomyelitis in Cuba: A historical perspective. Bulletin of the World Health Organization, 1999; 77(8):681-687.
37. Más Lago P, Gary HE, Jr., Pérez LS, Cáceres VM, Olivera JB, Puentes RP, Corredor MB, Jímenez P, Pallansch MA, González Cruz R. Poliovirus detection in wastewater and stools following an immunization campaign in Havana, Cuba. International Journal of Epidemiology, 2003; 32:772-777.
38. World Health Organization. Polio Laboratory Manual. Geneva; 2004 November. Report No.: WHO/IVB/04.10.
39. Glezen WP, Lamb GA, Belden EA, Chin TD. Quantitative relationship of preexisting homotypic antibodies to the excretion of attenuated poliovirus type 1. American Journal of Epidemiology, 1966; 83(2):224-237.
40. John TJ. Role of injectable and oral polio vaccines in polio eradication. Expert Reviews of Vaccines, 2009; 8(1):5-8.
41. Dick GWA, Dane DS, McAlister J, Briggs M, Nelson R. Effect of previous Salk vaccination on excretion. British Medical Journal, 1961:266-269.
42. Glezen PW, McCollough RH, Lamb GA, Chin TDY. Quantitative relationship of preexisting homotypic antibodies to excretion of poliovirus types 1, 2, and 3 following the feeding of trivalent attenuated poliovirus vaccine. American Journal of Epidemiology, 1969; 90(2):146-156.
43. Plotkin SA, Pagano JS, Koprowski H. Vaccination of full-term infants with attenuated polioviruses. Pp. 294-301 in Proceedings of the 2nd International Conference on Live Poliomyelitis Vaccines. Washington, DC: Pan American Health Organization, 1960.
44. Siegert R, Enders-Ruckle G, Oehme J, Waller D. Der einfluß der prävakzinalen immunität auf die virusausscheidung und antikörperproduktion nach polio-schluckimpfung mit typ i (Sabin) [The effect of prevaccinal immunity on virus excretion and antibody production after polio immunization with type i (Sabin)]. Deutsche medizinische Wochenschrift, 1963;88(33):1586-1594.
45. Kok PW, Leeuwenburg J, Tukei P, van Wezel AL, Kapsenberg JG, van Steenis G, Galazka A, Robertson SE, Robinson D. Serological and virological assessment of oral and inactivated poliovirus vaccines in a rural population in Kenya. Bulletin of the World Health Organization, 1992; 70(1):93-103.
46. Gelfand HM, Potash L, LeBlanc DR, Fox JP. Revised preliminary report on the Louisiana observations of the natural spread within families of living vaccine strains of poliovirus. Pp. 203-217 in Proceedings of the 1st International Conference on Live Poliovirus Vaccines Washington, DC, 1959.
47. Gelfand HM, Potash L, Leblanc DR, Fox JP. Intrafamilial and interfamilial spread of living vaccine strains of polioviruses. Journal of the American Medical Association, 1959; 170(17):2039-2048.
48. Wehrle PF, Carbonaro O, Day PA, Whalen JP, Reichert R, Portnoy B. Transmission of polioviruses. III. Prevalence of polioviruses in pharyngeal secretions of infected household contacts of patients with clinical disease. Pediatrics, 1961; 27:762-764.
49. Wehrle PF, Hagen F, Carbonaro O. Transmission of polioviruses. II. Spread of attenuated poliovirus type III in a partially immunized school population. Pediatrics, 1961; 27:755-61.
50. Dong DX, Hu XM, Liu WJ, Li JS, Jin YC, Tan SG, Chen TQ, Fu JZ, Niu BY, Yu HM, Zhou Y. Immunization of neonates with trivalent oral poliomyelitis vaccine (Sabin). Bulletin of the World Health Organization, 1986; 64(6):853-860.
51. El-Sayed N, El-Gamal Y, Abbassy AA, Seoud I, Salama M, Kandeel A, Hossny E, Shawky A, Hussein HA, Pallansch MA, van der Avoort HG, Burton AH, Sreevatsava M, Malankar P, Wahdan MH, Sutter RW. Monovalent type 1 oral poliovirus vaccine in newborns. New England Journal of Medicine, 2008; 359(16):1655-1665.
52. Sabin AB, Michaels RH, Ziring P, Krugman S, Warren J. Effect of oral poliovirus vaccine in newborn children. II. Intestinal resistance and antibody response at 6 months in children fed type 1 vaccine at birth. Pediatrics, 1963; 31(4):641-650.
53. Sutter RW, John TJ, Jain H, Agarkhedkar S, Ramanan PV, Verma H, Deshpande JM, Singh AP, Sreevatsava M, Malankar P, Burton A, Chatterjee A, Jafari H, Aylward RB. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: A randomised, double-blind, controlled trial. Lancet, 2010; 376(9753):1682-1688.
54. Swartz TA, Skalska P, Gerichte Cg, Cockburn WC. Routine administration of oral polio vaccine in a subtropical area. Factors possibly influencing sero-conversion rates. Journal of Hygiene, 1972; 70(4):719-726.
55. Plotkin S, Koprowski H, Stokes J, Jr. Clinical trials in infants of orally administered attenuated poliomyelitis viruses. Pediatrics, 1959; 23(6):1041-1062.
56. Abraham R, Minor P, Dunn G, Modlin JF, Ogra PL. Shedding of virulent poliovirus revertants during immunization with oral poliovirus vaccine after prior immunization with inactivated polio vaccine. Journal of Infectious Diseases, 1993; 168(5):1105-1109.
57. Minor PD, Dunn G, Ramsay ME, Brown D. Effect of different immunisation schedules on the excretion and reversion of oral poliovaccine strains. Journal of Medical Virology, 2005; 75(1):153-160.
58. Ogra PL, Faden HS, Abraham R, Duffy LC, Sun M, Minor PD. Effect of prior immunity on the shedding of virulent revertant virus in feces after oral immunization with live attenuated poliovirus vaccines. Journal of Infectious Diseases, 1991; 164(1):191-194.
59. Ramsay ME, Begg NT, Gandhi J, Brown D. Antibody response and viral excretion after live polio vaccine or a combined schedule of live and inactivated polio vaccines. Pediatric Infectious Diseases Journal, 1994; 13(12):1117-1121.
60. Faden H, Modlin J, Thoms M, McBean A, Ferdon M, Ogra P. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: Systemic and local immune responses. Journal of Infectious Diseases, 1990; 162(6):1291-1297.
61. Asturias EJ, Dueger EL, Omer SB, Melville A, Nates SV, Laassri M, Chumakov K, Halsey NA. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants. Journal of Infectious Diseases, 2007; 196(5):692-698.
62. The Cuba IPV Study Collaborative Group. Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba. New England Journal of Medicine, 2007; 356(15):1536-1544.
63. Ion-Nedelcu N, Strebel PM, Toma F, Biberi-Moroeanu S, Combiescu M, Persu A, Aubert-Combiescu A, Plotkin SA, Sutter RW. Sequential and combined use of inactivated and oral poliovirus vaccines: Dolj district, Romania, 1992-1994. Journal of Infectious Diseases, 1997; 175(Suppl 1):S241-S246.
64. Laassri M, Lottenbach K, Belshe R, Wolff M, Rennels M, Plotkin S, Chumakov KM. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. Journal of Infectious Diseases, 2005; 192:2092-2098.
65. Modlin JF, Halsey NA, Thoms ML, Meschievitz CK, Patriarca PA. Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules. Baltimore area polio vaccine study group. Journal of Infectious Diseases, 1997; 175(Suppl 1):S228-S234.
66. Modlin JF. Mucosal immunity following oral poliovirus vaccine and enhanced potency inactivated poliovirus vaccine immunization. Pediatric Infectious Diseases Journal, 1991; 10(12):976-978.
67. Mohammed AJ, Al Awaidy S, Bawikar S, Kurup PJ, Elamir E, Shaban MM, Sharif SM, van der Avoort HG, Pallansch MA, Malankar P, Burton A, Sreevatsava M, Sutter RW. Fractional doses of inactivated poliovirus vaccine in Oman. New England Journal of Medicine, 2010; 362(25):2351-2359.
68. Public Health Laboratory Service. The excretion of type 1 poliovirus after challenge following primary immunization with quadruple, Salk, and Sabin vaccines. Monthly Bulletin of the Ministry of Health and Public Health Laboratory Service, 1965; 24:365-369.
69. Piirainen L, Stenvik M, Roivainen M, Eskola J, Beuvery EC, Hovi T. Randomised, controlled trial with the trypsin-modified inactivated poliovirus vaccine: Assessment of intestinal immunity with live challenge virus. Vaccine, 1999; 17(9-10):1084-1090.
70. Cohen-Abbo A, Culley BS, Reed GW, Sannella EC, Mace RL, Robertson SE, Wright PF. Seroresponse to trivalent oral poliovirus vaccine as a function of dosage interval. Pediatric Infectious Diseases Journal, 1994; 14(2):100-106.
71. Mallet L, Pelloquin F, Brigaud M, Caudrelier P, Bandet R, Xueref C, Fuchs F, Gibelin N, Goldman C, Moulin JC, de Fraipont F, Montagnon B, Peyron L, Aymard M. Comparative study of poliovirus excretion after vaccination of infants with two oral polio vaccines prepared on vero cells or on primary monkey kidney cells. Journal of Medical Virology, 1997; 52(1):50-60.
72. Samoilovich E, Roivainen M, Titov LP, Hovi T. Serotype-specific mucosal immune response and subsequent poliovirus replication in vaccinated children. Journal of Medical Virology, 2003; 71(2):274-280.
73. Maldonado YA, Peña-Cruz V, Sanchez MD, Logan L, Blandón S, Cantwell MF, Matsui SM, MillanVelasco F, Valdespino JL, Sepulveda J. Host and viral factors affecting the decreased immunogenicity of Sabin type 3 vaccine after administration of trivalent oral polio vaccine to rural Mayan children. Journal of Infectious Diseases, 1997; 175(3):545-553.
74. Horstmann DM, Niederman JC, Paul JR. Attenuated type 1 poliovirus vaccine: Its capacity to infect and to spread from vaccinees within an institutional population. Journal of the American Medical Association, 1959; 170(1):65-72.
75. Parent du Châtelet I, Merchant AT, Fisher-Hoch S, Luby SP, Plotkin SA, Moatter T, Agboatwalla M, McCormick JB. Serological response and poliovirus excretion following different combined oral and inactivated poliovirus vaccines immunization schedules. Vaccine, 2003; 21(15):1710-1718.
76. Sutter RW, Suleiman AJ, Malankar P, Al-Khusaiby S, Mehta F, Clements GB, Pallansch MA, Robertson SE. Trial of a supplemental dose of four poliovirus vaccines. New England Journal of Medicine, 2000; 343(11):767-773.
77. Lu CY, Kao CL, Lee CY, Lee PI, Huang LM. Immunogenicity and fecal poliovirus excretion in sequential use of inactivated and oral poliovirus vaccines. Journal of the Formosan Medical Association, 2001; 100(8):513-518.
78. Swartz TA, Green MS, Handscher R, Sofer D, Cohen-Dar M, Shohat T, Habib S, Barak E, Dror Z, Somekh E, Peled-Leviathan T, Yulzari R, Libling A, Mendelson E, Shulman LM. Intestinal immunity following a combined enhanced inactivated polio vaccine/oral polio vaccine programme in Israel. Vaccine, 2008; 26(8):1083-1090.
79. Marine WM, Chin TD, Gravelle CR. Limitation of fecal and pharyngeal poliovirus excretion in Salk-vaccinated children. A family study during a type 1 poliomyelitis epidemic. American Journal of Hygiene, 1962; 76:173-195.
80. Gelfand HM, LeBlanc D, Fox JP, Potash L. Studies on the development of natural immunity to poliomyelitis in Louisiana. IV. Natural infections with polioviruses following immunization with a formalin-inactivated vaccine. American Journal of Hygiene, 1959; 70(3):312-327.
81. Vaccine Administration Subcommittee. Evaluation of Sabin live poliovirus vaccine in Japan. II. Clinical, virologic and immunologic effects of vaccine in children. Japanese Journal of Medical Science and Biology, 1966; 19(6):277-291.
82. Valtanen S, Roivainen M, Piirainen L, Stenvik M, Hovi T. Poliovirus-specific intestinal antibody responses coincide with decline of poliovirus excretion. Journal of Infectious Diseases, 2000; 182(1):1-5.
83. van der Sanden S, Pallansch MA, van de Kassteele J, El-Sayed N, Sutter RW, Koopmans M, van der Avoort HGAM. Shedding of vaccine viruses with increased antigenic and genetic divergence after vaccination of newborns with monovalent type 1 oral poliovirus vaccine. Journal of Virology, 2009; 83(17):8693-8704.
84. Drosdov SG, Shirman GA, Ashmarine EE. Dynamics of excretion of the three types of vaccine virus in vaccinated children and their contacts. Investigation of properties of virus isolates. Pp. 165-173 presented at the IVth Scientific Conference of the Institute of Poliomyelitis and Virus Encephalitis and the International Symposium on Live Poliovirus Vaccine, Moscow, 1961.
85. Horstmann DM, Paul JR, Godenne-McCrea M, Green RH, Opton EM, Holtzai, Niederman JC. Immunization of preschool children with oral poliovirus vaccine (Sabin). Journal of the American Medical Association, 1961; 178:693-701.
86. Kucharska Z. Excretion of live attenuated polioviruses in the faeces of orally vaccinated children. Comparison of two immunization schedules. Journal of Hygiene, Epidemiology, Microbiology and Immunology, 1985; 29(2):211-218.
87. John TJ, Jain H, Ravishankar K, Amaresh A, Verma H, Deshpande J, Pallansch MA, Singh AP, Sreevatsava M, Burton A, Malankar P, Chatterjee A, Sutter RW. Monovalent type 1 oral poliovirus vaccine among infants in India: Report of two randomized double-blind controlled clinical trials. Vaccine, 2011; 29(34):5793-5801.
88. Ginter V, Indulen M, Kanel I. Spread of vaccine virus in boarding children's institutions and households during immunization with live poliovirus vaccine. Pp. 558-590 presented at the IVth Scientific Conference of the Institute of Poliomyelitis and Virus Encephalitis and the International Symposium on Live Poliovirus Vaccine, Moscow, 1961.
89. Abbink F, Buisman AM, Doornbos G, Woldman J, Kimman TG, Conyn-van Spaendonck MAE. Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion. Journal of Infectious Diseases, 2005; 191(6):990-999.
90. Ogra PL. Mucosal immune response to poliovirus vaccines in childhood. Reviews of Infectious Diseases, 1984; 6(Suppl 2):S361-S368.
91. Ogra PL, Karzon DT. Formation and function of poliovirus antibody in different tissues. Progress in Medical Virology, 1971; 13:156-193.
92. Ogra PL, Ogra SS, al-Nakeeb S, Coppola PR. Local antibody response to experimental poliovirus infection in the central nervous system of rhesus monkeys. Infection and Immunity, 1973; 8(6):931-7.
93. Ogra PL, Fishaut M, Gallagher MR. Viral vaccination via the mucosal routes. Reviews of Infectious Diseases, 1980; 2:352-369.
94. Nishio O, Sumi J, Sakae K, Ishihara Y, Isomura S, Inouye S. Fecal IgA antibody responses after oral poliovirus vaccination in infants and elder children. Microbiology and Immunology, 1990; 34(8):683-689.
95. Buisman AM, Abbink F, Schepp RM, Sonsma JA, Herremans T, Kimman TG. Preexisting poliovirus-specific IgA in the circulation correlates with protection against virus excretion in the elderly. Journal of Infectious Diseases, 2008; 197(5):698-706.
96. Herremans TMPT, Reimerink JH, Buisman AM, Kimman TG, Koopmans MP. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. Journal of Immunology, 1999; 162:5011-5018.
97. Böttiger M. Polio immunity to killed vaccine: An 18-year follow-up. Vaccine, 1990; 8(5):443-445.
98. Faden H, Duffy L, Sun M, Shuff C. Long-term immunity to poliovirus in children immunized with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines. Journal of Infectious Diseases, 1993; 168(2):452-454.
99. Kelley PW, Petruccelli BP, Stehr-Green P, Erickson RL, Mason CJ. The susceptibility of young adult Americans to vaccine-preventable infections. A national serosurvey of US army recruits. Journal of the American Medical Association, 1991; 266(19):2724-9.
100. Nishio O, Ishihara Y, Sakae K, Nonomura Y, Kuno A, Yasukawa S, Inoue H, Miyamura K, Kono R. The trend of acquired immunity with live poliovirus vaccine and the effect of revaccination: Follow-up of vaccinees for ten years. Journal of Biological Standardization, 1984; 12(1):1-10.
101. Goffe A, Pollock TM, Shand FL. Vaccination of adults with a British oral poliomyelitis vaccine prepared from Sabin strains. British Medical Journal, 1961; 2(5247):272-274.
102. Smith JWG, Lee JA, Fletcher WB, Yetts R, Magrath DI, Perkins FT. The response to oral poliovaccine in persons aged 16-18 years. Journal of Hygiene Cambridge, 1976; 76:235-247.
103. Pirez MC, Olivera I, Diabarboure H, Montano A, Baranano R, Badia F, Bonnet MC. Seroprevalence of anti-polio antibodies in a population 7 months to 39 years of age in Uruguay: Implications for future polio vaccination strategies. Vaccine, 2009; 27(20):2689-2694.
104. Lamy ME, Cornu C, Desmyter J. Poliovirus antibodies in age groups: An assessment of obligatory vaccination in Belgium. Developments in Biological Standardization 1979; 43:207-213.
105. Trivello R, Renzulli G, Farisano G, Bonello C, Moschen M, Gasparini V, Benussi G. Persistence of poliovirus-neutralizing antibodies 2-16 years after immunization with live attenuated vaccine. A seroepidemiologic survey in the mainland of Venice. Epidemiology and Infection 1988; 101(3):605-609.
106. Schoub BD, Blackburn NK, McAnerney JM. Seroprevalence to polio in personnel at a virology institute. J Infect. 2001; 43(2):128-131.
107. Pagano JS, Böttiger M, Bonnevier JO, Gard S. The response and the lack of spread in Swedish school children given an attenuated poliovirus vaccine prepared in human diploid cell strain. American Journal of Hygiene, 1964; 79:74-85.
108. Verlinde JD, Wilterdink JB. A small-scale trial on vaccination and revaccination with live attenuated polioviruses in the Netherlands. Pp. 355-366 in First International Conference of Live Poliovirus Vaccine; Washington, DC: Pan American Sanitary Bureau, 1959.
109. Kogon A, Sigland I, Elveback LR, Fox JP. Oral poliovirus vaccination in middle income families. American Journal of Epidemiology, 1965; 82(1):14-26.
110. Weckx LY, Schmidt BJ, Herrmann AA, Miyasaki CH, Novo NF. Early immunization of neonates with trivalent oral poliovirus vaccine. Bulletin of the World Health Organization, 1992; 70(1):85-91.
111. Dowdle WR, van der Avoort HGAM, de Gourville EM, Delpeyroux F, Deshpande JM, Hovi T, Martín J, Pallansch MA, Kew OM, Wolff C. Containment of polioviruses after eradication: Characterizing risk to improve management. Risk Analysis, 2006; 26(6):1449-1469.
112. Smorodintsev A, Ilyenko V, Kurnosova M. Virological and immunological characteristics of vaccinal infection in children inoculated per os with a live poliomyelitis vaccine made from the Sabin strains. Pp. 312-323 presented at the 1st International Conference on Live Poliovirus Vaccines, Washington, DC, 1959.
113. Plotkin SA, Koprowski H, Richardson SN, Stokes J, Jr. Vaccination of families against poliomyelitis by feeding and by contact spread of living attenuated virus including studies of virus properties after human intestinal passage. Acta Paediatrica, 1960; 49:551-71.
114. Fox JP, Gelfand HM, LeBlanc DR, Rowan DF. The influence of natural and artificially induced immunity on alimentary infections with polioviruses. American Journal of Public Health, 1958; 48(9):1181-1192.
115. Fox JP, Gelfand HM, Leblanc DR, Conwell DP. Studies on the development of natural immunity to poliomyelitis in Louisiana: I. Over-all plan, methods and observations as to patterns of seroimmunity in the study group. American Journal of Hygiene, 1957; 65(3):344-366.
116. Gelfand HM, LeBlanc DR, Fox JP, Conwell DP. Studies on the development of natural immunity to poliomyelitis in Louisiana. II. Description and analysis of episodes of infection observed in study group households. American Journal of Hygiene, 1957; 65(3):367-385.
117. Chin TD, Marine WM, Hall EC, Gravelle CR, Speers JF. Poliomyelitis in Des Moines, Iowa, 1959. The influence of Salk vaccination on the epidemic pattern and the spread of the virus in the community. American Journal of Hygiene, 1961; 74:67-94.
118. Horstmann DM, Niederman JC, Riordan JT, Paul JR. The trial use of Sabin's attenuated type 1 poliovirus vaccine in a village in southern Arizona. American Journal of Hygiene, 1959; 70:169-184.
119. Melnick JL, Walton M, Isacson P, Cardwell W. Environmental studies of endemic enteric virus infections. I. Community seroimmune patterns and poliovirus infection rates. American Journal of Hygiene 1957; 65(1):1-28.
120. Stickle G. Observed and expected poliomyelitis in the United States, 1958-1961. American Journal of Public Health, 1964; 54:1222-1229.
121. Böttiger M. The elimination of polio in the Scandinavian countries. Public Health Reviews, 1993; 21(1-2):27-33.
122. Lapinleimu K. Elimination of poliomyelitis in Finland. Reviews of Infectious Diseases, 1984; 6(Suppl 2):S457-S460.
123. Dane DS, Dick GWA, Briggs M, Nelson R, McAlister J, Conolly JH, Haire M, McKeown CMB. Vaccination against poliomyelitis with live virus vaccines: 6. Changes in Sabin type II oral vaccine virus after human passage. British Medical Journal, 1961; 2(5247):259-265.
124. Bhatt PN, Brooks M, Fox JP. Extent of infection with poliomyelitis virus in household associates of clinical cases as determined serologically and by virus isolation using tissue culture methods. American Journal of Hygiene 1955; 61(3):287-301.
125. Fine PE, Carneiro IA. Transmissibility and persistence of oral polio vaccine viruses: Implications for the global poliomyelitis eradication initiative. American Journal of Epidemiology, 1999; 150(10):1001-1021.
126. Benyesh-Melnick M, Melnick JL, Ramos-Alvarez M. Poliomyelitis infection rate among Mexican children fed attenuated poliovirus vaccines. Presented at the 1st International Conference on Live Poliovirus Vaccines, 1959.
127. Sabin AB, Michaels RH, Spigland I, Pelon W, Rhim JS, Wehr RE. Community-wide use of oral poliovirus vaccine. Effectiveness of the Cincinnati program. American Journal of Diseases of Children, 1961; 101:546-567.
128. Oliver Wyman. The supply landscape and economics of IPV-containing vaccines: Key findings, 2010 May.
129. PATH. Improving the affordability of inactivated poliovirus vaccines (IPV) for use in low- and middle-income countries: An economic analysis of strategies to reduce the cost of routine IPV immunization. Seattle: PATH, 2010 April 20.
130. Sutter RW, Cáceres VM, Más Lago P. The role of routine immunization in the post-certification era. Bulletin of the World Health Organization, 2004; 82(1):31-8.
131. Barr RN, Bauer H, Kleinman H, Johnson EA, Martins da Silva M, Kimball AC. Use of orally administered live attenuated polioviruses as a vaccine in a community setting. Journal of the American Medical Association, 1959; 170(8):893-905.
132. Beale AJ, Davies JR, Thrower AL. Response to one dose of trivalent oral poliovaccine in children previously immunised with Salk vaccine: A comparison of liquid vaccine and a capsule presentation. Lancet, 1965; 1(7391):879-881.
133. Dömök I, Molnár E, Jancso A. Virus excretion after mass vaccination with attenuated polioviruses in Hungary. British Medical Journal, 1961:1410-1417.
134. Dömök I, Molnár E, Jancso A. Enterovirus isolation studies in connection with the polio vaccination program in Hungary 1959-60. Pp. 85-104 in Weisfeiler J (ed). The Control of Poliomyelitis by Live Poliovirus Vaccine. Budapest: Akademiai Kiadó, 1961.
135. Grassly NC, Jafari H, Bahl S, Durrani S, Wenger J, Sutter RW, Aylward RB. Mucosal immunity after vaccination with monovalent and trivalent oral poliovirus vaccine in India. Journal of Infectious Diseases, 2009; 200(5):794-801.
136. John TJ, Christopher S. Oral polio vaccination of children in the tropics. III. Intercurrent enterovirus infections, vaccine virus take and antibody response. American Journal of Epidemiology, 1975; 102(5):422-428.
137. John TJ. Oral polio vaccination of children in the tropics. II. Antibody response in relation to vaccine virus infection. American Journal of Epidemiology, 1975; 102(5):414-421.
138. John TJ, Jayabal P. Oral polio vaccination of children in the tropics. I. The poor seroconversion rates and the absence of viral interference. American Journal of Epidemiology, 1972; 96(4):263-269.
139. Koroleva G, Zhevandrova V, Voroshilova M, Taranova G, Chumakov M. Virologic and serologic survey of children in contact with those immunized with live poliovirus vaccine. Presented at the IVth Scientific Conference of the Institute of Poliomyelitis and Virus Encephalitis and the International Symposium on Live Poliovirus Vaccine, 1960.
140. Zhevandrova V, Koroleva G, Voroshilova M. The dynamics of vaccine strain excretion in oral immunization with trivalent live poliomyelitis vaccine. Pp. 174-180 Presented at the IVth Scientific Conference of the Institute of Poliomyelitis and Virus Encephalitis and the International Symposium on Live Poliovirus Vaccine, Moscow, 1960.
141. Levine S, Goldblum N, Friedman E. Virologic findings and antibody response of newborns fed multiple type oral poliomyelitis vaccine. American Journal of Hygiene, 1961; 74:95-103.
142. Buonagurio DA, Coleman JW, Patibandla SA, Prabhakar BS, Tatem JM. Direct detection of Sabin poliovirus vaccine strains in stool specimens of first-dose vaccinees by a sensitive reverse transcription-pcr method. Journal of Clinical Microbiology, 1999; 37(2):283-289.
143. Roca-Garcia M, Markham FS, Cox HR, Vargas-Mendez O, Guevara EC, Montoya JA. Poliovirus shedding and seroconversion. Journal of the American Medical Association, 1964; 188(7):639-646.
144. Sabin AB, Ramos-Alvarez M, Alvarez-Amezquita J, Pelon W, Michaels RH, Spigland I, Koch MA, Barnes JM, J.S. R. Live, orally given poliovirus vaccine: Effects of rapid mass immunization on population under conditions of massive enteric infection with other viruses. Journal of the American Medical Association, 1960; 173(14):1521-1526.
145. Wehrle PF, Reichert R, Carbonaro O, Portnoy B. Influence of prior active immunization on the presence of poliomyelitis virus in the pharynx and stools of family contacts of patients with paralytic poliomyelitis. Pediatrics, 1958; 21(3):353-361.
146. Bodian D, Paffenbarger RS, Jr. Poliomyelitis infection in households; frequency of viremia and specific antibody response. American Journal of Hygiene 1954; 60(1):83-98.
147. Isacson P, Melnick JL, Walton M. Environmental studies of endemic enteric virus infections. II. Poliovirus infections in household units. American Journal of Hygiene 1957; 65(1):29-42.